**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 6443**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (7): Liver transplant

**Role of cardiovascular intervention as a bridge to liver transplantation**

Raval Z *et al*. Evidence-based CV management in ESLD

Zankhana Raval, Matthew E Harinstein, James D Flaherty

**Zankhana Raval, James D Flaherty,** Bluhm Cardiovascular Institute, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, United States

**Matthew E Harinstein,** University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, PA 15219, United States

**Author contributions:** Raval Z contributed to the study idea, study design, literature search, and manuscript writing; Harinstein ME contributed to the manuscript writing and final revision of the article; Flaherty JD contributed to the study idea, literature search, manuscript writing and final revision of the article.

**Correspondence to: James D Flaherty, MD,** Bluhm Cardiovascular Institute, 676 North Saint Clair St. Suite 600, Chicago, IL 60611, United States. jflahert@nmh.org

**Telephone:** +1-312-9268948  **Fax:** +1-312-6949430

**Received:** October 17, 2013 **Revised:** January 11, 2014

**Accepted:** April 1, 2014

**Published online:**

**Abstract**

End stage liver disease (ESLD) is associated with many specific derangements in cardiovascular physiology, which influence perioperative outcomes and may profoundly influence diagnostic and management strategies in the preoperative period. This review focuses on evidence-based diagnosis and management of coronary, hemodynamic and pulmonary vascular disease in this population with an emphasis on specific strategies that may provide a bridge to transplantation. Specifically, we address the underlying prevalence of cardiovascular disease states in the ESLD population, and relevant diagnostic criteria thereof. We highlight traditional and non-traditional predictors of cardiovascular outcomes following liver transplant, as well as data to guide risk-factor based diagnostic strategies. We go on to discuss the alterations in cardiovascular physiology which influence positive- and negative- predictive values of standard noninvasive testing modalities in the ESLD population, and review the data regarding the safety and efficacy of invasive testing in the face of ESLD and its co-morbidities. Finally, based upon the totality of available data, we outline an evidence-based approach for the management of ischemia, heart failure and pulmonary vascular disease in this population. It is our hope that such evidence-driven strategies can be employed to more safely bridge appropriate candidates to liver transplant, and to improve their cardiovascular health and outcomes in the peri-operative period.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Perioperative management; Liver transplantation; Coronary heart disease; Cirrhotic cardiomyopathy; Heart failure; Pulmonary vascular disease

**Core tip:** The population of liver transplant candidates is rapidly evolving with respect to advanced age, etiology and co-morbidities. Consequently, the cardiovascular risk profiles of these candidates have increased. At the same time, the availability of interventions, both mechanical and pharmacologic, for cardiovascular conditions has allowed previously unsuitable candidates to go on to liver transplantation. Therefore, it is imperative to understand how to define the cardiovacular risk profile of liver transplant candidates and the pre-transplant treatment options available to them.

Raval Z, Harinstein ME, Flaherty JD. Role of cardiovascular intervention as a bridge to liver transplantation.

**Available from:**

**DOI:**

**CORONARY ARTERY DISEASE**

In light of the rising prevalence of coronary artery disease (CAD) among the general population, and the increasing age and co-morbidities among present-day liver transplant candidates, special care must be given to coronary evaluation and management prior to liver transplantation (LT)[1]. It has been estimated that more than one in four LT candidates with traditional coronary risk factors (Table 1) may have developed moderate coronary stenosis by the time of LT consideration even while asymptomatic and that the likelihood of obstructive CAD (> 70% coronary stenosis or > 50% left main stenosis) is greatest among candidates with ≥ 2 traditional cardiac risk factors[2-4]. In particular, age > 50 years and diabetes mellitus (DM) seem predictive of cardiac ischemia post-LT[5-9]. In one analysis, LT recipients with known CAD or DM had approximately 40% greater 5-year mortality than those without CAD or DM[10]. In a retrospective analysis of ESLD patients who underwent invasive angiography prior to LT, multi-vessel CAD of any severity was associated with increased mortality and postoperative hemodynamic instability[11]. It is therefore important to identify and treat patients at risk for coronary disease prior to liver transplantation given their elevated risk of postoperative ischemic complications[9,12,13].

Ischemic evaluation with exercise or pharmacologic stress testing (utilizing either echocardiographic or perfusion imaging) has been shown to have decreased predictive value in LT candidates when compared to the general population. (Table 2) Stress testing should be pursued based on careful, individualized evaluation of the candidate’s pretest probability for having CAD. In general, the ability to exercise to target heart rate is blunted in LT candidates, likely due to decreased beta-agonist transduction, and pharmacologic stress testing is usually favored[14]. For the same reason, LT candidates may not achieve desired chronotropy on dobumatine stress echocardiography (DSE). Indeed, those who do not achieve target heart rate or peak double product (heart rate x blood pressure) are felt to be at elevated risk of postoperative cardiovascular events[15]. DSE may have poor sensitivity (reported as low as 13%) and low negative predictive value (reported as low as 75%) among LT candidates[16-18]. Vasodilator perfusion imaging with nuclear SPECT (single photon emission computed tomography) may also have limited utility in the setting of the chronically vasodilated states seen in advanced liver disease[19]. Resting microvascular vasodilation in ESLD may effectively “decrease” available coronary flow reserve, which may in turn lead to apparent perfusion defects having lower-than-expected specificity for obstructive epicardial coronary disease (*i.e.* false-positive vasodilator stress test results)[20-24] (Table 2).

Non-alcoholic steatohepatitis (NASH) cirrhotic patients more commonly exhibit traditional coronary risk factors and associated CAD compared to patients with other etiologies of cirrhosis[25-29]. In addition, cirrhotic patients with concomitant renal dysfunction are also at elevated risk for coronary disease[30].

A direct visual assessment of the coronary artery anatomy should be considered for LT candidates with high pretest probability of CAD (≥ 2 traditional coronary risk factors, especially DM) in addition to those with ischemia on stress imaging. In one study of LT candidates without known CAD, greater than 30% were found to have at least moderate CAD on cardiac CT angiography[4]. CT angiography offers an attractive balance of safely and accuracy for this purpose. It can be offered to patients of normal habitus who are able to lie still, perform required breath holding maneuvers and who have a regular non-tachycardic rhythm[4,31,32]. Negative predictive value of normal or nonobstructrive findings on coronary CT angiography can approach 95%[33]. Invasive coronary angiography can also be performed safely in LT candidates even in the face of renal dysfunction and elevated bleeding risk[34-36]. Invasive angiography *via* a transradial approach has been advocated in LT candidates, if possible, to promote more reliable hemostasis in the setting of the often-profound coagulopathies and cytopenias seen with ESLD[37,38]. Revascularization of obstructive coronary disease may be pursued to improve symptom burden and cardiovascular mortality per ACC/AHA guidelines, and in cases where the burden of obstructive CAD would prohibit LT in an otherwise appropriate surgical candidate[24,39 40].

Revascularization if clinically indicated is felt to be safe, especially in the absence of significant varices, and can improve post-LT outcomes similar to those in LT candidates without significant CAD[41,42]. Treatment of thrombocytopenia and coagulopathy as well as minimal adequate sheath sizing may reduce vascular and bleeding complication rates to those observed patients without ESLD[43]. In general, bare metal stents are usually favored in this population to minimize duration of dual antiplatelet therapy and intendant bleeding risks. In select patients, coronary artery bypass grafting may also be performed prior to LT[44]. It has been suggested that advanced age, female gender, and the presence of clinical heart failure or ascites are predictors of mortality after coronary bypass, however these data must be interpreted with caution given low representation of cirrhotic patients in surgical study cohorts[45].

**CARDIOMYOPATHY AND HEART FAILURE**

Changes in cardiac morphology, chronotropy, systolic/diastolic performance and vascular resistance that are commonly seen in the setting of cirrhosis can compromise a patient’s ability to handle the hemodynamic stresses of LT. Specifically, ELSD has been associated with chamber enlargement and hypertrophy, decreased beta-agonist transduction with bradycardia and decreased chronotropic competence, high cardiac output +/- left ventricular outflow tract obstruction, and a milieu of circulating inflammatory mediators with cardiodepressant and systemic vasodilatory properties (low SVR)[46-52]. The term cirrhotic cardiomyopathy has been applied to these alterations in normal cardiovascular physiology, and such derangements can influence ventricular response to the sudden increase in preload that immediately follows transplant graft reperfusion[53-55]. Close monitoring and optimization of cardiac function is imperative to minimize post-transplant congestion and heart failure.

Common echocardiographic features of cirrhotic cardiomyopathy include hypertrophy out of proportion to hemodynamic load, impaired diastolic relaxation, and decreased contractile reserve[56-58]. Sudden increase in preload and gradual normalization of afterload post-transplant can unmask these cardiomyopathic features to produce overt heart failure[59-62]. Preoperative features predictive of clinically significant systolic heart failure after LT include elevated right-heart and pulmonary artery pressures prior to transplant[63]. In addition, the magnitude of early hemodynamic compromise (as measured by cardiac index and oxygen delivery within the first 12 h of transplant) has been correlated with risk of multiorgan failure and mortality[64]. With aggressive supportive management, the pathophysiologic features of cirrhotic cardiomyopathy may improve with LT over time[65]. Preoperative evaluation with transthoracic Doppler echocardiography can help identify those LT candidates at greatest risk for developing clinically significant heart failure syndromes postoperatively, in order to allow optimization of volume status and heart failure symptoms prior to LT, as well as planned aggressive management of heart failure after transplantation. Beta blockers, angiotensin converting enzyme inhibitors (ACE-i) and aldosterone antagonists are generally well tolerated post-LT, and should be continued in the absence of contraindications[66]. Study of beta blockers in cirrhosis suggests that carvedilol may best improve portal hypertension and hepatic venous pressure gradients *via* decreased splanchnic blood flow and decreased portocollateral resistance[67-69]. Dose adjustments of ACE-i and aldosterone antagonists may be required in the face of renal dysfunction with calcineurin inhibitors.

Resting transthoracic echocardiography is also useful for the identification and quantification of left ventricular outflow tract obstruction (LVOTO). LVOTO may be primarily functional (secondary to the high-flow state of ESLD) or primarily mechanical (secondary to obstructive hypertrophy). In either case, the risk for intraoperative hypotension is increased, especially in those LT candidates with resting LVOTO > 36 mmHg[70]. Careful preoperative evaluation is required to allow appropriate adjustment of anesthetic strategy in those at risk. Anesthetic strategies that avoid tachycardia, minimize preload depletion and limit inotropy are preferred in the setting of hemodynamically significant LVOTO[71-74]. Marked septal hypertrophy leading to symptomatic primary mechanical LVOTO may require invasive management for alcohol septal ablation if the degree of LVOTO would prohibit LT in an otherwise appropriate surgical candidate[75,76].

**PULMONARY HEART DISEASE**

Pulmonary heart disease is prevalent in LT candidates and is prognostic of postoperative outcomes. Vascular dilation in the pulmonary bed with intrapulmonary right-to-left shunting, ventilation-perfusion mismatch and hypoxemia is common in ESLD (termed hepatopulmonary syndrome), and does not portend worse outcomes with LT[77]. Pulmonary pressures and pulmonary vascular resistance are not markedly elevated in hepatopulomary syndrome, and its pathophysiologic features may in fact correct post-LT. In contrast, some LT candidates with portal hypertension can develop progressive pulmonary vascular constriction and remodeling with elevated pulmonary vascular resistance, a condition termed portopulmonary hypertension (POPH)[77,78]. POPH is estimated to be present in approximately 5%-10% of all LT candidates[79]. Extent of vascular remodeling in POPH is associated with increased mortality post-LT, with 50% mortality among those with POPH and mean pulmonary artery pressure (mPAP) 35-50 mmHg and near 100% mortality among those with POPH and mPAP > 50 mmHg[80,81]. Advanced untreated POPH with mPAP ≥ 35 mmHg, therefore, is considered a contraindication for LT. Aggressive screening and early referral to pulmonary hypertension specialists, ideally when right ventricular function is still preserved, may allow sufficient lowering of pulmonary pressures to allow LT[82-85].

Diagnosis of POPH should not be made on the basis of elevated pulmonary pressures alone. Baseline preoperative transthoracic echocardiography should be the initial screening strategy for the identification of PH in this population. A diagnosis of mild to moderate PH based on the estimation of the pulmonary artery systolic pressure on echocardiography has not been associated with worse outcomes. Thus for cases of worse PH, further assessment is warranted. Volume overload, left ventricular failure and high cardiac output can all contribute to elevated pulmonary pressures without conferring the same degree of perioperative risk. If there is evidence of right ventricular dysfunction or pulmonary hypertension on transthoracic echocardiography, the patient should be referred for invasive hemodynamics to differentiate pulmonary arterial from pulmonary venous hypertension. Accurate diagnosis of prohibitive POPH can only be made if mPAP is ≥ 35 mmHg and pulmonary vascular resistance is > 3 Woods units in the setting of a normal pulmonary capillary wedge pressure (PCWP) of < 15 mmHg. If PCWP is elevated, repeat invasive hemodynamics are warranted after appropriate diuresis or volume management as clinically tolerated. Finally, clinical management of underlying lung disease and other potentially reversible contributors to pulmonary hypertension should not be neglected.

Structural heart disease is prevalent in the general population, and atrial septal defects (ASD) or patent foramen ovalae (PFO) may also be found in LT candidates. ASD may be associated with shunt physiology and potential alterations in pulmonary vascular resistance over the long-term, theoretically contributing to risk of right-heart failure after transplant. The presence of PFO prior to LT has not been associated with worse outcomes in case series[86]. Existing data does not support excluding patients for transplant consideration based upon the presence of ASD or PFO[87].

**CONCLUSION**

CAD, cirrhotic cardiomyopathy and pulmonary heart disease are among the more common cardiovascular maladies affecting patients with ESLD. When epicardial coronary atherosclerosis is felt to prohibit LT, revascularization with either CABG surgery or PCI should be considered. In general, percutaneous revascularization is a safe and effective therapy for obstructive CAD among LT candidates, and is valuable in optimizing otherwise suitable surgical candidates to allow downstream transplantation. During PCI, bare metal stents are generally preferred to minimize duration of dual antiplatelet therapy and bleeding risk. The pathophysiologic features of cirrhotic cardiomyopathy may be unmasked by changes in preload and afterload with LT, and should therefore prompt aggressive volume and hemodynamic management as clinically tolerated prior to transplantation, with continued close monitoring and therapy throughout the perioperative period. The presence of LVOTO > 35 mmHg may warrant adjustment of anesthetic strategy to optimize intraoperative volume status to maintain preload, heart rate to maintain diastolic filling and to avoid excessive inotropy. Portopulmonary hypertension (pulmonary vascular remodeling with elevated resistance) is associated with risk of fulminant right-heart failure and increased perioperative mortality, especially with mPAP ≥ 35 mmHg. We recommend invasive hemodynamic assessment in all LT candidates with suggestion of right ventricular dysfunction and/or at least moderate pulmonary hypertension by echocardiography. Patients with volume overload (PCWP > 15 mmHg) and/or other reversible etiologies of pulmonary hypertension should be aggressively treated for these etiologies, with repeat assessment of pulmonary hemodynamics once euvolemic and better clinically compensated. Patients meeting hemodynamic criteria for moderate to severe POPH as detailed above should have early referral to a pulmonary hypertension specialist for advanced medical and intraoperative therapies to facilitate consideration for LT.

**REFERENCES**

1 **Xia VW**, Taniguchi M, Steadman RH. The changing face of patients presenting for liver transplantation. *Curr Opin Organ Transplant* 2008; **13**: 280-284 [PMID: 18685318 DOI: 10.1097/MOT.0b013e328300a070]

2 **Tiukinhoy-Laing SD**, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, Flamm S, Davidson CJ, Gheorghiade M. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. *Am J Cardiol* 2006; **98**: 178-181 [PMID: 16828588 DOI: 10.1016/j.amjcard.2006.01.089]

3 **Johnston SD**, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. *Transplantation* 2002; **73**: 901-906 [PMID: 11923689 DOI: 10.1097/00007890-200203270-00012]

4 **Keeling AN**, Flaherty JD, Davarpanah AH, Ambrosy A, Farrelly CT, Harinstein ME, Flamm SL, Abecassis MI, Skaro AI, Carr JC, Gheorghiade M. Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experience. *J Cardiovasc Med* (Hagerstown) 2011; **12**: 460-468 [PMID: 21610507]

5 **Appleton CP**, Hurst RT. Reducing coronary artery disease events in liver transplant patients: moving toward identifying the vulnerable patient. *Liver Transpl* 2008; **14**: 1691-1693 [PMID: 19025924 DOI: 10.1002/lt.21660]

6 **Carey WD**, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, Vogt DP, Mayes JT, Westveer MK, Easley KA. The prevalence of coronary artery disease in liver transplant candidates over age 50. *Transplantation* 1995; **59**: 859-864 [PMID: 7701580]

7 **Kryzhanovski VA**, Beller GA. Usefulness of preoperative noninvasive radionuclide testing for detecting coronary artery disease in candidates for liver transplantation. *Am J Cardiol* 1997; **79**: 986-988 [PMID: 9104922 DOI: 10.1016/S0002-9149(97)00030-1]

8 **Muñoz SJ**. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. *Liver Transpl Surg* 1995; **1**: 29-38 [PMID: 9346598]

9 **Plotkin JS**, Johnson LB, Rustgi V, Kuo PC. Coronary artery disease and liver transplantation: the state of the art. *Liver Transpl* 2000; **(4 Suppl 1)**: S53-S56 [PMID: 10915192 DOI: 10.1002/lt.500060511]

10 **Yoo HY**, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. *Transplantation* 2002; **74**: 1007-1012 [PMID: 12394846 DOI: 10.1097/00007890-200210150-00019]

11 **Yong CM**, Sharma M, Ochoa V, Abnousi F, Roberts J, Bass NM, Niemann CU, Shiboski S, Prasad M, Tavakol M, Ports TA, Gregoratos G, Yeghiazarians Y, Boyle AJ. Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation. *Liver Transpl* 2010; **16**: 1242-1248 [PMID: 21031539]

12 **Diedrich DA**, Findlay JY, Harrison BA, Rosen CB. Influence of coronary artery disease on outcomes after liver transplantation. *Transplant Proc* 2008; **40**: 3554-3557 [PMID: 19100436 DOI: 10.1016/j.transproceed.2008.08.129]

13 **Plotkin JS**, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. *Liver Transpl Surg* 1996; **2**: 426-430 [PMID: 9346688 DOI: 10.1002/lt.500020604]

14 **Ma Z**, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. *Am J Physiol* 1994; **267**: G87-G93 [PMID: 8048535]

15 **Umphrey LG**, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. *Liver Transpl* 2008; **14**: 886-892 [PMID: 18508373 DOI: 10.1002/lt.21495]

16 **Harinstein ME**, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, Flamm SL, Blei AT, Bonow RO, Abecassis M, Gheorghiade M. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. *Am J Transplant* 2008; **8**: 1523-1528 [PMID: 18510630 DOI: 10.1111/j.1600-6143.2008.02276.x]

17 **Williams K**, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. *Transplantation* 2000; **69**: 2354-2356 [PMID: 10868639 DOI: 10.1097/00007890-200006150-00023]

18 **Donovan CL**, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, Armstrong WF. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. *Transplantation* 1996; **61**: 1180-1188 [PMID: 8610415 DOI: 10.1097/00007890-199604270-00011]

19 **Davidson CJ**, Gheorghiade M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, Sundaram SA, Flamm SL, Blei AT, Abecassis MI, Bonow RO. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. *Am J Cardiol* 2002; **89**: 359-360 [PMID: 11809445 DOI: 10.1016/S0002-9149(01)02244-5]

20 **Aydinalp A**, Bal U, Atar I, Ertan C, Aktaş A, Yildirir A, Ozin B, Mudderisoglu H, Haberal M. Value of stress myocardial perfusion scanning in diagnosis of severe coronary artery disease in liver transplantation candidates. *Transplant Proc* 2009; **41**: 3757-3760 [PMID: 19917381 DOI: 10.1016/j.transproceed.2009.06.219]

21 **Yilmaz Y**, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, Oflaz H, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. *Atherosclerosis* 2010; **211**: 182-186 [PMID: 20181335]

22 **Matsuo S**, Nakamura Y, Matsumoto T, Takahashi M, Kinoshita M. Detection of coronary microvascular disease by means of cardiac scintigraphy. *Can J Cardiol* 2002; **18**: 183-186 [PMID: 11875588]

23 **Bhutani S**, Tobis J, Gevorgyan R, Sinha A, Suh W, Honda HM, Vorobiof G, Packard RR, Steadman R, Wray C, Busuttil R, Tseng CH. Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. *Am J Cardiol* 2013; **111**: 1057-1061 [PMID: 23337839]

24 **Ehtisham J**, Altieri M, Salamé E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. *Liver Transpl* 2010; **16**: 550-557 [PMID: 20440764]

25 **Kadayifci A**, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. *J Hepatol* 2008; **49**: 595-599 [PMID: 18662837 DOI: 10.1016/j.jhep.2008.05.024]

26 **Targher G**, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. *Diabet Med* 2006; **23**: 403-409 [PMID: 16620269 DOI: 10.1111/j.1464-5491.2006.01817.x]

27 **Targher G**, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. *Atherosclerosis* 2007; **191**: 235-240 [PMID: 16970951 DOI: 10.1016/j.atherosclerosis.2006.08.021]

28 **Targher G**, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010; **363**: 1341-1350 [PMID: 20879883]

29 **Vanwagner LB**, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. *Hepatology* 2012; **56**: 1741-1750 [PMID: 22611040]

30 **Cholongitas E**, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. *Eur J Gastroenterol Hepatol* 2009; **21**: 744-750 [PMID: 20160527 DOI: 10.1097/MEG.0b013e328308bb9c]

31 **Chae WY**, Hwang S, Yoon YI, Kang MC, Moon DB, Song GW, Park GC, Jung DH, Namgoong JM, Jung SW, Yoon SY, Kim JJ, Hwang GS, Lee SG. Clinical value of preoperative coronary risk assessment by computed tomographic arteriography prior to adult living donor liver transplantation. *Transplant Proc* 2012; **44**: 415-417 [PMID: 22410031]

32 **Jodocy D**, Abbrederis S, Graziadei IW, Vogel W, Pachinger O, Feuchtner GM, Jaschke W, Friedrich G. Coronary computer tomographic angiography for preoperative risk stratification in patients undergoing liver transplantation. *Eur J Radiol* 2012; **81**: 2260-2264 [PMID: 21665396]

33 **Cassagneau P**, Jacquier A, Giorgi R, Amabile N, Gaubert JY, Cohen F, Muller C, Jolibert M, Louis G, Varoquaux A, Vidal V, Bartoli JM, Moulin G. Prognostic value of preoperative coronary computed tomography angiography in patients treated by orthotopic liver transplantation. *Eur J Gastroenterol Hepatol* 2012; **24**: 558-562 [PMID: 22367157]

34 **MacDonald LA**, Beohar N, Wang NC, Nee L, Chandwaney R, Ricciardi MJ, Benzuly KH, Meyers SN, Gheorghiada M, Davidson CJ. A comparison of arterial closure devices to manual compression in liver transplantation candidates undergoing coronary angiography. *J Invasive Cardiol* 2003; **15**: 68-70 [PMID: 12556618]

35 **Sharma M**, Yong C, Majure D, Zellner C, Roberts JP, Bass NM, Ports TA, Yeghiazarians Y, Gregoratos G, Boyle AJ. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. *Am J Cardiol* 2009; **103**: 742-746 [PMID: 19231345 DOI: 10.1016/j.amjcard.2008.10.037]

36 **Azarbal B**, Poommipanit P, Arbit B, Hage A, Patel J, Kittleson M, Kar S, Kaldas FM, Busuttil RW. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. *Liver Transpl* 2011; **17**: 809-813 [PMID: 21425429]

37 **Rao SV**, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. *J Am Coll Cardiol* 2010; **55**: 2187-2195 [PMID: 20466199]

38 **Jacobs E**, Singh V, Damluji A, Shah NR, Warsch JL, Ghanta R, Martin P, Alfonso CE, Martinez CA, Moscucci M, Cohen MG. Safety of transradial cardiac catheterization in patients with end-stage liver disease. *Catheter Cardiovasc Interv* 2014; **83**: 360-366 [PMID: 23723127]

39 **Axelrod D**, Koffron A, Dewolf A, Baker A, Fryer J, Baker T, Frederiksen J, Horvath K, Abecassis M. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. *Liver Transpl* 2004; **10**: 1386-1390 [PMID: 15497147 DOI: 10.1002/lt.20244]

40 **Benedetti E**, Massad MG, Chami Y, Wiley T, Layden TJ. Is the presence of surgically treatable coronary artery disease a contraindication to liver transplantation? *Clin Transplant* 1999; **13**: 59-61 [PMID: 10081636 DOI: 10.1034/j.1399-0012.1999.t01-1-130109.x]

41 **Russo MW**, Pierson J, Narang T, Montegudo A, Eskind L, Gulati S. Coronary artery stents and antiplatelet therapy in patients with cirrhosis. *J Clin Gastroenterol* 2012; **46**: 339-344 [PMID: 22105182]

42 **Wray C**, Scovotti JC, Tobis J, Niemann CU, Planinsic R, Walia A, Findlay J, Wagener G, Cywinski JB, Markovic D, Hughes C, Humar A, Olmos A, Sierra R, Busuttil R, Steadman RH. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. *Am J Transplant* 2013; **13**: 184-191 [PMID: 23126562]

43 **Pillarisetti J**, Patel P, Duthuluru S, Roberts J, Chen W, Genton R, Wiley M, Candipan R, Tadros P, Gupta K. Cardiac catheterization in patients with end-stage liver disease: safety and outcomes. *Catheter Cardiovasc Interv* 2011; **77**: 45-48 [PMID: 20506280]

44 **Marui A**, Kimura T, Tanaka S, Miwa S, Yamazaki K, Minakata K, Nakata T, Ikeda T, Furukawa Y, Kita T, Sakata R. Coronary revascularization in patients with liver cirrhosis. *Ann Thorac Surg* 2011; **91**: 1393-1399 [PMID: 21396626]

45 **Shaheen AA**, Kaplan GG, Hubbard JN, Myers RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. *Liver Int* 2009; **29**: 1141-1151 [PMID: 19515218 DOI: 10.1111/j.1478-3231.2009.02058.x]

46 **Alqahtani SA**, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. *Semin Liver Dis* 2008; **28**: 59-69 [PMID: 18293277 DOI: 10.1055/s-2008-1040321]

47 **Baik SK**, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. *Orphanet J Rare Dis* 2007; **2**: 15 [PMID: 17389039 DOI: 10.1186/1750-1172-2-15]

48 **Gaskari SA**, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 329-337 [PMID: 16741552 DOI: 10.1038/ncpgasthep0498]

49 **Liu H**, Song D, Lee SS. Cirrhotic cardiomyopathy. *Gastroenterol Clin Biol* 2002; **26**: 842-847 [PMID: 12434095]

50 **Møller S**, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. *Heart* 2002; **87**: 9-15 [PMID: 11751653 DOI: 10.1136/heart.87.1.9]

51 **Myers RP**, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. *Liver Transpl* 2000; **(4 Suppl 1)**: S44-S52 [PMID: 10915191 DOI: 10.1002/lt.500060510]

52 **Garg A**, Armstrong WF. Echocardiography in liver transplant candidates. *JACC Cardiovasc Imaging* 2013; **6**: 105-119 [PMID: 23328568]

53 **Brems JJ**, Takiff H, McHutchison J, Collins D, Biermann LA, Pockros P. Systemic versus nonsystemic reperfusion of the transplanted liver. *Transplantation* 1993; **55**: 527-529 [PMID: 8456472 DOI: 10.1097/00007890-199303000-00013]

54 **Shi XY**, Xu ZD, Xu HT, Jiang JJ, Liu G. Cardiac arrest after graft reperfusion during liver transplantation. *Hepatobiliary Pancreat Dis Int* 2006; **5**: 185-189 [PMID: 16698572]

55 **Xu ZD**, Xu HT, Yuan HB, Zhang H, Ji RH, Zou Z, Fu ZR, Shi XY. Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 34-39 [PMID: 22251468]

56 **De Marco M**, Chinali M, Romano C, Benincasa M, D'Addeo G, D'Agostino L, de Simone G. Increased left ventricular mass in pre-liver transplantation cirrhotic patients. *J Cardiovasc Med* (Hagerstown) 2008; **9**: 142-146 [PMID: 18192806 DOI: 10.2459/JCM.0b013e3280c7c29c]

57 **Pozzi M**, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. *Hepatology* 1997; **26**: 1131-1137 [PMID: 9362352]

58 **Ward CA**, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. *Gastroenterology* 2001; **121**: 1209-1218 [PMID: 11677214 DOI: 10.1053/gast.2001.28653]

59 **Levine JM**, Kindscher JD. Cardiac failure after orthotopic liver transplantation. *Anesth Analg* 1994; **78**: 179-180 [PMID: 8267160 DOI: 10.1213/00000539-199401000-00032]

60 **Sampathkumar P**, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, Plevak DJ. Post-liver transplantation myocardial dysfunction. *Liver Transpl Surg* 1998; **4**: 399-403 [PMID: 9724477 DOI: 10.1002/lt.500040513]

61 **Stewart KS**, Rhim CH, Bahrain ML, Ashkezari ZD, Ozdemirli M, Fishbein TM, Johnson LB, Lu AD, Plotkin JS. Nonischemic cardiomyopathy after orthotopic liver transplantation: a report of three cases and a review of the literature. *Liver Transpl* 2005; **11**: 573-578 [PMID: 15838869 DOI: 10.1002/lt.20410]

62 **Dowsley TF**, Bayne DB, Langnas AN, Dumitru I, Windle JR, Porter TR, Raichlin E. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. *Transplantation* 2012; **94**: 646-651 [PMID: 22918216]

63 **Eimer MJ**, Wright JM, Wang EC, Kulik L, Blei A, Flamm S, Beahan M, Bonow RO, Abecassis M, Gheorghiade M. Frequency and significance of acute heart failure following liver transplantation. *Am J Cardiol* 2008; **101**: 242-244 [PMID: 18178414 DOI: 10.1016/j.amjcard.2007.08.056]

64 **Nasraway SA**, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, Benotti PN. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. *Chest* 1995; **107**: 218-224 [PMID: 7813282 DOI: 10.1378/chest.107.1.218]

65 **Torregrosa M**, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genescà J. Cardiac alterations in cirrhosis: reversibility after liver transplantation. *J Hepatol* 2005; **42**: 68-74 [PMID: 15629509 DOI: 10.1016/j.jhep.2004.09.008]

66 **Hunt SA**, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009;**119**: e391-e479 [PMID: 19324966 DOI: 10.1161/CIRCULATIONAHA.109.192065]

67 **Tripathi D**, Hayes PC. The role of carvedilol in the management of portal hypertension. *Eur J Gastroenterol Hepatol* 2010; **22**: 905-911 [PMID: 20093937]

68 **Lin HC**, Huang YT, Wei HC, Yang YY, Lee TY, Wang YW, Hou MC, Lee SD. Hemodynamic effects of one week of carvedilol administration on cirrhotic rats. *J Gastroenterol* 2006; **41**: 361-368 [PMID: 16741616 DOI: 10.1007/s00535-006-1782-5]

69 **Bañares R**, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, Abraldes JG, De Diego A, Albillos A, Bosch J. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. *Hepatology* 2002; **36**: 1367-1373 [PMID: 12447861]

70 **Maraj S**, Jacobs LE, Maraj R, Contreras R, Rerkpattanapipat P, Malik TA, Manzarbeitia C, Munoz S, Rothstein K, Kotler MN. Inducible left ventricular outflow tract gradient during dobutamine stress echocardiography: an association with intraoperative hypotension but not a contraindication to liver transplantation. *Echocardiography* 2004; **21**: 681-685 [PMID: 15546368 DOI: 10.1111/j.0742-2822.2004.03068.x]

71 **Harley ID**, Jones EF, Liu G, McCall PR, McNicol PL. Orthotopic liver transplantation in two patients with hypertrophic obstructive cardiomyopathy. *Br J Anaesth* 1996; **77**: 675-677 [PMID: 8957992 DOI: 10.1093/bja/77.5.675]

72 **Lim YC**, Doblar DD, Frenette L, Fan PH, Poplawski S, Nanda NC. Intraoperative transesophageal echocardiography in orthotopic liver transplantation in a patient with hypertrophic cardiomyopathy. *J Clin Anesth* 1995; **7**: 245-249 [PMID: 7669317 DOI: 10.1016/0952-8180(94)00049-A]

73 **Cywinski JB**, Argalious M, Marks TN, Parker BM. Dynamic left ventricular outflow tract obstruction in an orthotopic liver transplant recipient. *Liver Transpl* 2005; **11**: 692-695 [PMID: 15915494 DOI: 10.1002/lt.20440]

74 **Roy D**, Ralley FE. Anesthetic management of a patient with dynamic left ventricular outflow tract obstruction with systolic anterior movement of the mitral valve undergoing redo-orthotopic liver transplantation. *J Cardiothorac Vasc Anesth* 2012; **26**: 274-276 [PMID: 21514844]

75 **Hage FG**, Bravo PE, Zoghbi GJ, Bynon JS, Aqel RA. Hypertrophic obstructive cardiomyopathy in liver transplant patients. *Cardiol J* 2008; **15**: 74-79 [PMID: 18651389]

76 **Paramesh AS**, Fairchild RB, Quinn TM, Leya F, George M, Van Thiel DH. Amelioration of hypertrophic cardiomyopathy using nonsurgical septal ablation in a cirrhotic patient prior to liver transplantation. *Liver Transpl* 2005; **11**: 236-238 [PMID: 15666373 DOI: 10.1002/lt.20327]

77 **Hoeper MM**, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. *Lancet* 2004; **363**: 1461-1468 [PMID: 15121411 DOI: 10.1016/S0140-6736(04)16107-2]

78 **Grace JA**, Angus PW. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. *J Gastroenterol Hepatol* 2013; **28**: 213-219 [PMID: 23190201]

79 **Kuo PC**, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. *Transplantation* 1999; **67**: 1087-1093 [PMID: 10232556 DOI: 10.1097/00007890-199904270-00001]

80 **Swanson KL**, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. *Am J Transplant* 2008; **8**: 2445-2453 [PMID: 18782292 DOI: 10.1111/j.1600-6143.2008.02384.x]

81 **Martínez-Palli G**, Taurà P, Balust J, Beltrán J, Zavala E, Garcia-Valdecasas JC. Liver transplantation in high-risk patients: hepatopulmonary syndrome and portopulmonary hypertension. *Transplant Proc* 2005; **37**: 3861-3864 [PMID: 16386564 DOI: 10.1016/j.transproceed.2005.09.119]

82 **Porres-Aguilar M**, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. *Ann Hepatol* 2008; **7**: 321-330 [PMID: 19034231]

83 **Hemnes AR**, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. *Liver Transpl* 2009; **15**: 15-19 [PMID: 19109843 DOI: 10.1002/lt.21479]

84 **Melgosa MT**, Ricci GL, García-Pagan JC, Blanco I, Escribano P, Abraldes JG, Roca J, Bosch J, Barberà JA. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. *Liver Transpl* 2010; **16**: 348-356 [PMID: 20209595]

85 **Ramsay M**. Portopulmonary hypertension and right heart failure in patients with cirrhosis. *Curr Opin Anaesthesiol* 2010; **23**: 145-150 [PMID: 20124995]

86 **Alba AC**, Verocai Flaman F, Granton J, Delgado DH. Patent foramen ovale does not have a negative impact on early outcomes in patients undergoing liver transplantation. *Clin Transplant* 2011; **25**: 151-155 [PMID: 20156223]

87 **Harinstein ME**, Iyer S, Mathier MA, Flaherty JD, Fontes P, Planinsic RM, Edelman K, Katz WE, Lopez-Candales A. Role of baseline echocardiography in the preoperative management of liver transplant candidates. *Am J Cardiol* 2012; **110**: 1852-1855 [PMID: 23021513]

**P-Reviewer:** Eghtesad B **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Traditional cardiac risk factors**

|  |
| --- |
| **Positive risk factors** |
| Age: male ≥ 45 yr, female ≥ 55 yr or premature menopause without estrogen replacement therapy |
| Family history of premature coronary disease: definite myocardial infarction or sudden death before age 55 yr in male first-degree relative and before age 65 yr in female first-degree relative |
| Current cigarette smoking |
| Hypertension: blood pressure > 140/90 mmHg, or an antihypertensive medication |
| HDL cholesterol < 40 mg/dL (1.03 mmol/L) |
| **Negative risk factors (subtract one risk factor if present)** |
| HDL cholesterol ≥ 60 mg/dL (1.55 mmol/L) |

Data from Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285: 2486.

**Table 2 Utility of non-invasive testing for coronary artery disease detection in liver transplant candidates (using coronary angiography as the gold standard)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Screening modality** | **Positive predictive value** | **Negative predictive value** |
| Harinstein *et al*[16] | DSE | 22 | 75 |
| Donovan *et al*[18] | DSE | 33 | 100 |
| Williams *et al*[17] | DSE | 0 | 86 |
| Davidson *et al*[19] | SPECT | 22 | 77 |
| Aydinalp *et al*[20] | SPECT | 15 | 100 |
| Bhutani *et al*[23] | SPECT | 23 | 93 |

DSE: Dobutamine stress echocardiography; SPECT: Single photon emission computed tomography.